#1 Clinical Trials Search in Europe

Glofitamab

Glofitamab is an innovative bispecific antibody being studied in clinical trials for the treatment of various types of relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). This article explores the ongoing research on glofitamab’s efficacy, safety, and potential as a new therapeutic option for patients who have exhausted standard treatments.

Table of Contents

What is Glofitamab?

Glofitamab is a new type of cancer medication that belongs to a class of drugs called bispecific antibodies. It’s also known by the brand name Columvi®, manufactured by Roche[2]. This innovative treatment is designed to help your immune system fight certain types of blood cancers more effectively[1].

How Does Glofitamab Work?

Glofitamab works in a unique way by connecting two important parts of your immune system:

  • It attaches to a protein called CD20, which is found on the surface of cancerous B-cells (a type of white blood cell).
  • At the same time, it connects to CD3, a protein on your T-cells (another type of immune cell that fights infections and cancer).

By bringing these cells together, glofitamab helps your T-cells recognize and attack the cancerous B-cells more effectively[7]. This clever design allows your body’s own immune system to target the cancer cells more precisely.

What Conditions Does Glofitamab Treat?

Glofitamab is primarily being studied and used to treat certain types of B-cell lymphomas. These are cancers that affect the lymphatic system, a part of your body’s immune defenses. The main conditions being targeted include:

  • Diffuse Large B-Cell Lymphoma (DLBCL): This is the most common type of non-Hodgkin lymphoma. It’s a fast-growing cancer that affects B-cells[1].
  • Relapsed or Refractory DLBCL: This refers to DLBCL that has either come back after treatment (relapsed) or didn’t respond well to previous treatments (refractory)[3].
  • Richter Syndrome: This is a rare condition where chronic lymphocytic leukemia (CLL) transforms into an aggressive form of lymphoma, usually DLBCL[6].

Glofitamab is especially promising for patients who have tried other treatments without success, offering a new hope for those with difficult-to-treat lymphomas.

How is Glofitamab Administered?

Glofitamab is given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The treatment schedule typically looks like this:

  • Before starting glofitamab, you’ll usually receive a single dose of another medication called obinutuzumab. This helps reduce the risk of side effects[1].
  • Glofitamab is then given in cycles, with each cycle lasting about 21 days.
  • In the first cycle, you’ll receive smaller “step-up” doses to help your body adjust to the treatment.
  • After that, you’ll typically receive a full dose every 3 weeks[6].

The exact dosing and schedule may vary depending on your specific condition and how you respond to the treatment.

Current Clinical Trials

Glofitamab is currently being studied in several clinical trials to better understand its effectiveness and safety. These trials are looking at:

  • Using glofitamab in combination with other cancer treatments to potentially improve outcomes[1].
  • Testing glofitamab in patients who have not responded to or relapsed after other treatments, including CAR-T cell therapy[2].
  • Evaluating glofitamab’s effectiveness in treating Richter Syndrome[6].
  • Studying glofitamab in real-world settings to understand how it performs outside of controlled clinical trials[8].

Potential Side Effects

Like all medications, glofitamab can cause side effects. Some of the most important ones to be aware of include:

  • Cytokine Release Syndrome (CRS): This is an inflammatory response that can cause fever, chills, and other flu-like symptoms. It’s usually manageable but can be serious in some cases[6].
  • Neurological effects: Some patients may experience confusion, difficulty speaking, or other neurological symptoms[1].
  • Low blood cell counts: Glofitamab can affect your blood cell production, potentially leading to an increased risk of infections, anemia, or bleeding[1].

Your healthcare team will monitor you closely for these and other side effects throughout your treatment.

Future Research and Combinations

Researchers are exploring several exciting avenues for the future use of glofitamab:

  • Combining glofitamab with other targeted therapies to potentially enhance its effectiveness[7].
  • Using glofitamab as a maintenance therapy to help prevent cancer recurrence in patients who have responded to initial treatment[4].
  • Investigating glofitamab’s potential in treating other types of B-cell cancers beyond DLBCL[5].

These ongoing studies aim to expand our understanding of how best to use glofitamab and potentially improve outcomes for patients with B-cell lymphomas.

Aspect Details
Drug Name Glofitamab (also known as Columvi®)
Primary Indications Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Aggressive B-cell Non-Hodgkin Lymphomas
Mechanism of Action Bispecific antibody targeting CD20 on B-cells and CD3 on T-cells
Administration Intravenous infusion, often with step-up dosing
Key Clinical Trials Phase II studies for R/R DLBCL, combination therapies, and real-world effectiveness
Primary Outcomes Complete response rate, progression-free survival, overall survival
Safety Considerations Monitoring for cytokine release syndrome and other adverse events
Combination Approaches Being studied with chemotherapy regimens and other novel agents

FAQ

  • What is glofitamab? Glofitamab is a bispecific antibody that binds to CD20 on B-cells and CD3 on T-cells. It is designed to bring T-cells close to cancer cells, activating the immune system to fight the lymphoma.
  • What types of lymphoma is glofitamab being studied for? Glofitamab is primarily being studied for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), as well as other aggressive B-cell non-Hodgkin lymphomas and Richter syndrome.
  • How is glofitamab administered? Glofitamab is typically given intravenously (IV) in cycles. It often uses a step-up dosing schedule, starting with lower doses and increasing over time to reduce the risk of side effects.
  • What are the main goals of the clinical trials studying glofitamab? The main goals are to assess the safety and efficacy of glofitamab, including its ability to induce complete responses, improve progression-free survival, and extend overall survival in patients with relapsed/refractory B-cell lymphomas.
  • Are there any notable side effects of glofitamab? While side effects can vary, one important potential side effect being monitored is cytokine release syndrome (CRS). Some trials use pre-treatment with other medications like obinutuzumab to help reduce the risk of CRS.

Ongoing Clinical Trials on Glofitamab

  • Study of glofitamab, obinutuzumab and tocilizumab in patients with mantle cell lymphoma relapsed or refractory after CAR‑T therapy

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • A study evaluating glofitamab and a drug combination for patients with relapsed or refractory diffuse large B-cell lymphoma.

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark France Germany Poland Spain

  • Study on the Effects of Maplirpacept, Glofitamab, and Obinutuzumab in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplant

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Spain

  • Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

  • Study on the Safety and Effects of Englumafusp Alfa with Obinutuzumab and Glofitamab for Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Italy Spain

  • Study on the Safety and Effectiveness of Glofitamab with R-CHOP for High-Risk Patients with Untreated Diffuse Large B-Cell Lymphoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France The Netherlands Poland Spain

  • Study of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory Lymphomas After CAR T-cell Therapy

    Not recruiting

    1 1 1
    Investigated drugs:
    France

Glossary

  • Bispecific antibody: A type of engineered antibody that can bind to two different targets simultaneously, in this case CD20 on B-cells and CD3 on T-cells.
  • Diffuse Large B-Cell Lymphoma (DLBCL): An aggressive type of non-Hodgkin lymphoma that affects B-cells and is the most common form of lymphoma in adults.
  • Relapsed/Refractory (R/R): Refers to cancer that has returned after treatment (relapsed) or has not responded to initial treatment (refractory).
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Cytokine Release Syndrome (CRS): A condition that can occur as a side effect of certain cancer treatments, causing fever, nausea, and other flu-like symptoms.
  • Obinutuzumab: A monoclonal antibody used in some trials as a pre-treatment before glofitamab to help reduce the risk of side effects.
  • Richter Syndrome: A rare condition where chronic lymphocytic leukemia (CLL) transforms into an aggressive lymphoma, usually DLBCL.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment.

References

  1. https://clinicaltrials.eu/trial/study-on-the-effects-of-maplirpacept-glofitamab-and-obinutuzumab-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-not-eligible-for-stem-cell-transplant/
  2. https://clinicaltrials.gov/study/NCT06552572
  3. https://clinicaltrials.gov/study/NCT06481826
  4. https://clinicaltrials.gov/study/NCT06050694
  5. https://clinicaltrials.gov/study/NCT06497452
  6. https://clinicaltrials.gov/study/NCT06186648
  7. https://clinicaltrials.gov/study/NCT06534437
  8. https://clinicaltrials.gov/study/NCT06656234